Allena Pharma gains hyperoxaluria portfolio from Althea
This article was originally published in Scrip
Executive Summary
Allena Pharmaceuticals, a US biotech set up last November to develop nonsystemic oral protein therapeutics for metabolic and orphan diseases, has obtained the exclusive worldwide rights to Althea Technologies' broad hyperoxaluria portfolio to assist in the development of its own therapy for hyperoxaluria – a condition for which there are currently no effective pharmacological treatments.